Vaccine Trials Articles & Analysis
30 news found
The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. ...
Clínica Universidad de Navarra has completed a randomised controlled study of Ondine Biomedical’s nasal photodisinfection technology in fully vaccinated COVID-19 patients with early symptoms of COVID-19. “Top-line results from this clinical trial suggest that nasal photodisinfection treatment rapidly and substantially suppresses SARS-CoV-2 ...
Utilizing its custom HQ plasmid offering which, being manufactured to the principles of GMP, serves as a phase-appropriate solution for early clinical trials, Ziphius Vaccines will benefit from accelerated timelines without compromising on quality. ...
FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients Next steps for development of VBI-1901 : Q3 2022: Expected initiation of randomized, controlled clinical study in recurrent GBM patients with potential to support accelerated approval application Q4 2022: Expected initiation of randomized, controlled evaluation in primary GBM patients as part ...
The double-blinded trial is testing Calviri’s vaccine aimed at broadly preventing cancers in dogs. ...
ByCalviri
Median overall survival and 18-month overall survival data continue to show improvements over historical controls1 One patient remains on protocol progression-free beyond two years, with a sustained 93% tumor reduction relative to baseline Next steps : Recurrent GBM: randomized, controlled evaluation with potential to support accelerated approval application expected to initiate in Q3 2022 ...
Researchers running the University of Oxford-led Com-COV programme have launched a further national study assessing different options for a (third dose) booster vaccination for young people aged 12 to 15. Backed through funding from the Vaccines Taskforce and National Institute for Health Research (NIHR), the Com-COV 3 trial will seek to recruit ...
INOVIO is evaluating candidate VGX-3100 in two Phase 3 trials for precancerous high-grade cervical dysplasia caused by HPV-16 and/or HPV-18. INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 trial. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & ...
We have also completed enrollment in a Phase 1b trial for Lassa fever, a Phase 1b trial for an Ebola vaccine booster, as well as the first part of our Phase 2 trial for Middle East Respiratory Syndrome (MERS), showcasing the depth and breadth of our DNA medicines pipeline to support global public health efforts against potential ...
INOVIO is evaluating candidate VGX-3100 in two Phase 3 trials for precancerous high-grade cervical dysplasia caused by HPV-16 and/or HPV-18. INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 trial. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & ...
Upcoming Milestones: Topline data from Phase 1 expected H1 2022 Initiation of Phase 2/3 oral COVID-19 vaccine trials expected H2 2022 Phase 2 NASH Trial: 50% Enrollment Completed Over 50% of patients have been enrolled in the U.S. and Israel in our double-blind Phase 2 trial of ORMD-0801 for the treatment of ...
This trial is being run by ApolloBio and is similar in design to REVEAL2. ...
(www.ora-vax.com), has screened and enrolled the first participant in a Phase 1 clinical trial of its oral virus-like particle (VLP) COVID-19 vaccine in Johannesburg, South Africa. The open-label trial anticipates enrolling 24 participants who have not received either a COVID-19 vaccine or contracted the virus. Participants will ...
Testing INO-4802, a Pan-COVID-19 vaccine candidate, against Omicron. INOVIO has been proactively developing INO-4802 as a second-generation Pan-COVID 19 vaccine to potentially address future variants. ...
The trial will assess whether INO-4201 can be used as a booster in healthy volunteers previously vaccinated with rVSV-ZEBOV (Ervebo®1), an FDA- and EMA-approved viral-based vector Ebola vaccine. ...
The potential advantages of INOVIO's vaccine platform include how quickly DNA vaccine candidates can be designed and manufactured; the stability of the vaccine candidates, which do not require freezing in storage and transport; and the immune response and tolerability that have been observed in clinical trials. With more than ...
The Vaccine Against Canine Cancer Study (VACCS) trial (www.vaccs.org) reported its formal two-year evaluation of the safety of a vaccine to prevent cancer in healthy dogs. ...
ByCalviri
BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine candidate. ...
(“Micron” or the “Company”), a leader in dissolving, microneedle-based vaccine and drug delivery, today announced that it has initiated a Phase 1/2 clinical trial of its microneedle-based measles-rubella (“MR”) vaccine. ...
Further longer-term stability studies are underway, and the Company is planning the immunogenicity studies needed to determine the next development steps to progress the novel vaccine formulations towards clinical trials. Measles and Rubella vaccines are typically maintained in a lyophilized (freeze-dried) form that requires reconstitution in ...